Pharmacotherapy in depressed children and adolescents

World Journal of Biological Psychiatry

Volumn 12, Issue SUPPL. 1, 2011, Pages 11-15

  Taurines, Regina ^a   Gerlach, Manfred ^a   Warnke, Andreas ^a   Thome, Johannes ^b   Wewetzer, Christoph ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c Hospital of Child and Adolescent Psychiatry and Psychotherapy   (Germany)

Author keywords

Antidepressants; Child and adolescent psychiatry; Depressive episode; Selective serotonin reuptake inhibitor; Tricyclic antidepressant

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LAMOTRIGINE; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; OXCARBAZEPINE; PLACEBO; SEDATIVE AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ADOLESCENT; AGITATION; ANXIETY DISORDER; BULIMIA; CARDIOTOXICITY; CHILD; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MONITORING; GROUPS BY AGE; HUMAN; LETHARGY; MAJOR DEPRESSION; OBSESSIVE COMPULSIVE DISORDER; PATIENT COMPLIANCE; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REVIEW; RISK BENEFIT ANALYSIS; SEROTONIN SYNDROME; SLEEP DISORDER; SUICIDAL IDEATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CHILD; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FLUOXETINE; HUMANS; OFF-LABEL USE; PSYCHOTHERAPY; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; SUICIDAL IDEATION;

EID: 80052766986     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2011.600295     Document Type: Review

References (45)

1. Ambrosini PJ. 2000. A review of pharmacotherapy of major depression in children and adolescents. Psychiat Serv 51: 627-633. (Pubitemid 30256638)
2. Andrade C, Bhakta SG, Singh NM. 2006. Controversy revisited: Selective serotonin reuptake inhibitors in paediatric depression. World J Biol Psychiatry 7:251-260. (Pubitemid 44650535)
3. Bailly D. 2008. Benefits and risks of using antidepressants in children and adolescents. Expert Opin Drug Saf 7:9-27. (Pubitemid 351222960)
4. Baldessarini RJ. 1989. Current status of antidepressants: clinical pharmacology and therapy. J Clin Psychiatry 50:117-126. (Pubitemid 19117705)
5. Bridge JA, Jyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, et al. 2007. Clinical response and risk for suicidal ideation and suicide attempts in pediatric antidepressant treatment. J Am Med Assoc 297:1683-1696.
6. Campbell M, Cueva JE. 1995. Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II. J Am Acad Child Adolesc Psychiatry 34:1262-1272.
7. Carvalho AF, Cavalcante JL, Castelo MS, Lima MC. 2007. Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther 32:415-428. (Pubitemid 47404283)
8. Courtney DB. 2004. Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: a systematic review of published randomized controlled trials. Can J Psychiatry 49:557-563. (Pubitemid 39237312)
9. Dugas M, Mouren MC, Halfon O, Moron P. 1985. Treatment of childhood and adolescent depression with mianserin. Acta Psychiatr Scand Suppl 320:48-53. (Pubitemid 16219441)
10. Edwarts JG, Anderson I. 1999. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57:507-533. (Pubitemid 29196919)
11. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, et al. 1997. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Ach Gen Psychiatry 54:1031-1037. (Pubitemid 27476099)
12. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, et al. 2002. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205-1215. (Pubitemid 38338040)
13. Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y. 2007. Venla-faxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 46:479-488. (Pubitemid 46622756)
14. Emslie GJ, Kennard BD, Mayes TL, Nightingale-Teresi J, Carmody T, Hughes CW, et al. 2008. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry 165:459-467. (Pubitemid 351694289)
15. Fegert JM, Herpertz-Dahlmann B. 2005. Serotoninwiederaufnah-mehemmer im Kindes-und Jugendalter. Warnhinweise der Behörden, Analyseergebnisse und Empfehlungen. Nervenarzt 76:1330-1339.
16. Fleischhaker Ch, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex, Warke A, Schulz E, et al. 2003. Indikationsspektrum und Nebenwirkungen von " neuen " Antidepressiva im Rahmen eines multizentrischen Arzneimittelmonitorings- eine Pilots-tudie. In Lemkuhl U, editor. Psychotherapie und Psychophar- makotherapie im Kindes-und Jugendalter. Göttingen: Vandenhoeck & Ruprecht.
17. Gerlach M, Baving L, Fegert J. 2006. Therapie mit Lithium-Salzen in der Kinder-und Jugendpsychiatrie-Klinische Wirksamkeit und praktische Empfehlungen. Z Kinder-Jugendpsychiatrie 34:181-189. (Pubitemid 43872937)
18. Gerlach M, KlampflK, Mehler-Wex C, Warnke A. Besonder-heiten der Therapie mit Psychopharmaka im Kindes-und Jugendalter. 2009. In: Gerlach M, Mehler-Wex C, Walitza S, Warnke A, Wewetzer C, editors. Psychopharmaka im Kindes-und Jugendalter. 2nd ed. Wien, New York: Springer. p. 73-88.
19. Haapasalo-Pesu KM, Vuola T, Lahelma L, Marttunen M. 2004. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study. J Child Adolesc Psychopharmacol 14:175-184. (Pubitemid 38988784)
20. Hammad TA, Laughren T, Racoosin J. 2006. Suicidality in pedi-atric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332-339. (Pubitemid 43345358)
21. Hazell P, O' Connell D, Heathcote D, Robertson J, Henry D. 1995. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. Br Med J 310:897-901.
22. Hazell P, O' Connell D, Heathcote D, Henry D. 2002. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2:CD002317.
23. Jorm AF, Allen NB, O'Donnell CP, Parslow RA, Purcell R, Morgan AJ. 2006. Effectiveness of complementary and self-help treatments for depression in children and adolescents. Med J Aust 185:368-372. (Pubitemid 44540798)
24. Kölch M, Fegert JM. 2006. [Medical treatment of depression in children and adolescents] Prax Kinderpsychol Kinderpsychiatr 56:224-233 [Review, in German].
25. Lane RM. 1996. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol Suppl 5:31-61. (Pubitemid 27049280)
26. Laux G, Baumann P, Hiemke C. 2007. TDM group of the Arbe-itsgemeinschaft Neuropsychopharmakologie und Pharmakopsy-chiatrie. Therapeutic drug monitoring of antidepressants-clinical aspects. J Neural Transm Suppl 72:261-267 [Review].
27. Lind AB, Reis M, Bengtsson F, Jonzier-Perey M, Powell Golay K, et al. 2009. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enan-tiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet 48:63-70.
28. Mandoki MW, Tapia MR, Tapia MA, Sumner GS, Parker JL. 1997. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull 33:149-154. (Pubitemid 27184210)
29. March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. 2007. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 64:1132-1143.
30. Masand PS, Gupta S. 2002. Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 14:175-182. (Pubitemid 36172566)
31. Mulrow CD, Williams JW Jr, Trivedi M, Chiquette E, Aguilar C, Cornell JE, et al. 1998. Treatment of depression-newer phar-macotherapies. Psychopharmacol Bull 34:409-795.
32. Papanikolaou K, Richardson C, Pehlivanidis A, Papadopoulou-Daifoti Z. 2006. Efficacy of antidepressants in child and adolescent depression: a meta-analytic study. J Neural Transm 113:399-415. (Pubitemid 43201106)
33. Pössel P, Hautzinger M. 2006. Effekte pharmakologischer und psychotherapeutischer Interventionen auf Depressionen bei Kindern und Jugendlichen. Z Kinder Jugendpsychiatr Psy-chother 34:243-255. (Pubitemid 44204674)
34. Safer DJ, Zito JM. 2006. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol 16:159-169.
35. Schlamp D. 1999. Remergil in der Kinder-und Jugendpsychi-atrie. Psychiatr Dialog 3:8-9.
36. Schmauss M, Messer T. 2007. [Augmentation strategies for therapy resistant depression-a review]. Psychiatr Prax 34:165-174. (Pubitemid 46910033)
37. Schulte-Markwort M, Richterich A, Forouher N. 2008. Affektive Störungen. In: Herpertz-Dahlmann B, Resch F, Schulte-Markwort M, Warnke A, editors. Entwicklungspsychiatrie. Bio-psychologische Grundlagen und die Entwicklung psychischer Störungen. 2nd ed. Stuttgart: Schattauer. p. 784-792.
38. Simeon J, Nixon MK, Milin R, Jovanovic R, Walker S. 2005. Open-label pilot study of St. John's wort in adolescent depression. J Child Adolesc Psychopharmacol 15:293-301. (Pubitemid 40734108)
39. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. 2002. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepres-sants: a meta-analysis. Br J Psychiatry 180:396-404. (Pubitemid 34499333)
40. Curry J, Wells K, Fairbank J, Burns B, et al 2009, The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up, Am J Psychiatry. 166. 1141-1149.
41. Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ. 2008. Efficacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry 193:10-17. (Pubitemid 351946803)
42. Wagner KD. Pharmacotherapy for major depression in children and adolescents. 2005. Prog Neuropsychopharmacol Biol Psychiatry 29:819-826. (Pubitemid 40897799)
43. Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Green-baum MS, et al. 2003. Sertraline Pediatric Depression Study Group. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. J Am Med Assoc 290:1033-1041. (Pubitemid 37430443)
44. Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Hey-dorn WE. 2004. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 161:1079-1083. (Pubitemid 38735994)
45. Weller EB, Weller RA. 2000. Treatment options in the management of adolescent depression. J Affect Disord Suppl 1:23-28.